{
  "docId": "019de071-38a0-778d-8d39-45a206af86ac",
  "docSlug": "8e68c7763c84d1b485e12f828c3b0d7e",
  "documentTitle": "argenx SE | Investor Day Presentation Deck | 69 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 69,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a structured layout to define the disease state and market opportunity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-38a0-778d-8d39-45a206af86ac/24",
  "deckHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac",
  "deckJsonHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac.json",
  "deckAnchorHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.81
      },
      "kind": "callout",
      "text": "Significant market opportunity with ~33K eligible patients in the U.S.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e39309c-d96d-40d1-8149-dca1b1e75556",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.72
      },
      "kind": "callout",
      "text": "Myositis subsets mediated by autoantibodies: immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc37e9a7-5752-4e11-9674-9855dfa7cb53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.17,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "(1) Meyer et al., Rheumatology. 2015; (2) Pinal-Fernandez et al., Curr Rheumatol Rep. 2018; (3) Schmidt, Journal of Neuromuscular Diseases. 2018",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee0358a0-28cb-485e-a94b-730da6a20bfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "subtitle",
      "text": "Rare, severe autoimmune disorders characterized by chronic muscle inflammation, pain and impaired quality of life; no FDA-approved therapies for myositis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23376557-6fd5-447f-a669-91656966661b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.94,
        "x": 0.03,
        "y": 0.26
      },
      "kind": "table",
      "text": "Prevalence, Hallmark, Treatment, Burden columns with associated details",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1331f448-3cab-4004-8170-ac7ab12b74d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Idiopathic Inflammatory Myopathy (IIM) or Myositis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70b469d3-2015-4020-b9a1-d7caeac410ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "1e07c265-a857-4ccc-baa8-32d47166cdc5",
      "evidence": "The slide presents a problem statement on Idiopathic Inflammatory Myopathy (IIM) or Myositis.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 24,
      "beatId": "00c05735-0296-42af-85b4-d63d3913b672",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "Discussion of myositis and its pathophysiology",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 24,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "997aa06c-e939-48b0-b970-55ff94a49394",
      "evidence": "Discussion of current treatment limitations",
      "position": 0,
      "objective": "Highlight the need for new treatments in myositis",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}